Literature DB >> 33208457

SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals.

Cecilie Bo Hansen1, Ida Jarlhelt1, Laura Pérez-Alós1, Lone Hummelshøj Landsy2, Mette Loftager2, Anne Rosbjerg1, Charlotte Helgstrand3, Jais Rose Bjelke3, Thomas Egebjerg3, Joseph G Jardine4, Charlotte Sværke Jørgensen5, Kasper Iversen6, Rafael Bayarri-Olmos1, Peter Garred1, Mikkel-Ole Skjoedt7,8.   

Abstract

Globally, the COVID-19 pandemic has had extreme consequences for the healthcare system and has led to calls for diagnostic tools to monitor and understand the transmission, pathogenesis, and epidemiology, as well as to evaluate future vaccination strategies. In this study, we have developed novel, to our knowledge, flexible ELISA-based assays for specific detection of human SARS-CoV-2 Abs against the receptor-binding domain, including an Ag sandwich ELISA relevant for large population screening and three isotype-specific assays for in-depth diagnostics. Their performance was evaluated in a cohort of 350 convalescent participants with previous COVID-19 infection, ranging from asymptomatic to critical cases. We mapped the Ab responses to different areas on protein N and S and showed that the IgM, A, and G Ab responses against receptor-binding domain are significantly correlated to the disease severity. These assays and the data generated from them are highly relevant for diagnostics and prognostics and contribute to the understanding of long-term COVID-19 immunity.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Year:  2020        PMID: 33208457     DOI: 10.4049/jimmunol.2000898

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19.

Authors:  David J Gregory; Augustin Vannier; Akiro H Duey; Tyler J Roady; Richard K Dzeng; Maia N Pavlovic; Michael H Chapin; Sonia Mukherjee; Hannah Wilmot; Nic Chronos; Richelle C Charles; Edward T Ryan; Regina C LaRocque; Tyler E Miller; Wilfredo F Garcia-Beltran; Julia C Thierauf; A John Iafrate; Steven Mullenbrock; Mark D Stump; Randall K Wetzel; Roberto D Polakiewicz; Vivek Naranbhai; Mark C Poznansky
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

2.  Relationship between Acute-Phase Symptoms and Immunoglobulin G Seropositivity up to Eight Months after COVID-19.

Authors:  Ladislav Štěpánek; Magdaléna Janošíková; Marie Nakládalová; Lubomír Štěpánek; Antonín Tihelka; Alena Boriková; Renata Večeřová; Pavel Sauer
Journal:  Medicina (Kaunas)       Date:  2022-05-26       Impact factor: 2.948

3.  Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases.

Authors:  Zitta Barrella Harboe; Sebastian Rask Hamm; Laura Pérez-Alós; Pradeesh Sivapalan; Helene Priemé; Torgny Wilcke; Peter Kjeldgaard; Saher Shaker; Alexander Svorre Jordan; Dina Leth Møller; Line Dam Heftdal; Johannes Roth Madsen; Rafael Bayarri-Olmos; Cecilie Bo Hansen; Mia Marie Pries-Heje; Rasmus Bo Hasselbalch; Kamille Fogh; Jose Juan Almagro Armenteros; Linda Hilsted; Erik Sørensen; Birgitte Lindegaard; Andrea Browatzki; Tor Biering-Sørensen; Ruth Frikke-Schmidt; Sisse Rye Ostrowski; Kasper Karmark Iversen; Henning Bundgaard; Susanne Dam Nielsen; Peter Garred; Jens-Ulrik Stæhr Jensen
Journal:  BMJ Open Respir Res       Date:  2022-07

4.  Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients.

Authors:  Ekaterina Garanina; Shaimaa Hamza; Robert J Stott-Marshall; Ekaterina Martynova; Maria Markelova; Yuriy Davidyuk; Venera Shakirova; Neha Kaushal; Manoj Baranwal; Ilsiyar M Khaertynova; Albert Rizvanov; Toshana L Foster; Svetlana Khaiboullina
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 6.064

5.  Recurrent injection-site reactions after incorrect subcutaneous administration of a COVID-19 vaccine.

Authors:  M Gyldenløve; L Skov; C B Hansen; P Garred
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-26       Impact factor: 9.228

6.  Antibodies: what makes us stronger.

Authors:  Natalia T Freund
Journal:  Hum Vaccin Immunother       Date:  2021-05-25       Impact factor: 4.526

7.  Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review.

Authors:  Julie Perry; Selma Osman; James Wright; Melissa Richard-Greenblatt; Sarah A Buchan; Manish Sadarangani; Shelly Bolotin
Journal:  PLoS One       Date:  2022-04-08       Impact factor: 3.240

8.  Evidence for antibody as a protective correlate for COVID-19 vaccines.

Authors:  Kristen A Earle; Donna M Ambrosino; Andrew Fiore-Gartland; David Goldblatt; Peter B Gilbert; George R Siber; Peter Dull; Stanley A Plotkin
Journal:  Vaccine       Date:  2021-05-24       Impact factor: 3.641

9.  Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020.

Authors:  Zacharoula Bogogiannidou; Matthaios Speletas; Alexandros Vontas; Dimitrios J Nikoulis; Katerina Dadouli; Maria A Kyritsi; Varvara A Mouchtouri; Paraskevi Mina; Lemonia Anagnostopoulos; Michalis Koureas; Vasileios Karavasilis; Olga Nikou; Ourania Pinaka; Pavlos C Thomaidis; Kornilia Kadoglou; Konstantinos Bedevis; Natalia Spyrou; Alexandros A Eleftheriou; Vassiliki Papaevangelou; Achilleas Gikas; Alkiviadis Vatopoulos; Evangelia E Ntzani; Panagiotis Prezerakos; Sotirios Tsiodras; Christos Hadjichristodoulou
Journal:  Vaccines (Basel)       Date:  2021-05-13

10.  Deep learning identifies antigenic determinants of severe SARS-CoV-2 infection within T-cell repertoires.

Authors:  John-William Sidhom; Alexander S Baras
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.